Paclitaxel gastrointestinal cancer

Data on two of these new taxanes, namely BMS-184476 (29) and BMS-188797 (29a), were published by Bristol-Myers-Squibb (BMS), which also developed Paclitaxel [96]. In a comparative preclinical study, both analogues were found to have cytotoxic potency similar to Paclitaxel but overcome two different forms of Paclitaxel resistance. BMS-184476 was found to be clearly superior to Paclitaxel especially on A2780 ovarian carcinoma, HCT/pk, a moderately Paclitaxel-resistant colon carcinoma and L2987 lung carcinoma. BMS 184476 is currently in phase II clinical trials in breast, NSCLC, oesophageal and gastrointestinal cancers [97]. 

In a phase I study of intraperitoneal paclitaxel in patients with advanced ovarian cancer, severe abdominal pain was the dose-limiting toxicity at doses over 175 mg/rr [57 ]. Significant gastrointestinal adverse reactions have been noted in other trials of intrap eritoneal paclitaxel chemotherapy, and this has limited its usefulness as a means of administering chemotherapy via this route [58, 597]. 

---